scispace - formally typeset
S

Stefan Faderl

Researcher at University of Texas MD Anderson Cancer Center

Publications -  586
Citations -  36426

Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.

Papers
More filters
Journal ArticleDOI

Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Modified Augmented Berlin-Frankfurt-Muenster (ABFM) Therapy

Michael Rytting, +10 more
- 18 Nov 2011 - 
TL;DR: Induction success, by morphology and flow cytometry, has been satisfactory with this regimen and Hepatic toxicity has resolved completely within two weeks in almost all pts as has the CNS toxicity.
Journal ArticleDOI

Outcomes of Patients (pts) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Hyper-CVAD-Based Chemotherapy Regimens: MD Anderson Case Series

Naveen Pemmaraju, +6 more
- 18 Nov 2011 - 
TL;DR: The characteristics and outcome of all pts with BPDCN who were referred to us and treated with various Hyper-CVAD-based regimens were reviewed to identify patterns of disease and response that might be useful for future pts.
Journal ArticleDOI

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

Gloria Mattiuzzi, +7 more
- 16 Nov 2006 - 
TL;DR: Targeted therapy has emerged as an alternative for patients (pts) 60 years or older with hematologic malignancies and these approaches produce fewer and less severe side effects than conventional chemotherapy and could potentially decrease mortality.
Journal ArticleDOI

Clofarabine Combinations in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C).

Stefan Faderl, +9 more
- 16 Nov 2005 - 
TL;DR: A phase I study of clofarabine with idarubicin (I) alone and with ara-C (A) [CIA] in pts with relapsed AML and high-grade MDS and preliminary results indicate feasibility of the combinations.
Journal ArticleDOI

Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study

Stefan Faderl, +5 more
- 01 Sep 2019 -